Lonza Group is a Basel, Switzerland–based multinational life sciences company specializing in the development, manufacturing and support of products for the pharmaceutical, biotechnology and specialty ingredients markets. As a leading contract development and manufacturing organization (CDMO), Lonza offers end-to-end solutions ranging from early-stage process development and clinical supply through commercial manufacturing of small molecules, biologics, cell and gene therapies. In addition, the company produces a range of chemical intermediates and microbial control products for the consumer care, agriculture and industrial sectors.
Founded in 1897 in the Swiss canton of Valais to exploit local hydropower for acetylene production, Lonza has evolved through decades of innovation and strategic acquisitions. The company expanded its footprint into the United States and Asia in the 1970s and 1980s, and more recently strengthened its biologics capabilities with the acquisition of Capsugel from Pfizer in 2017. Over its history, Lonza has consistently reinvested in facility expansions, bioprocess technologies and quality-assurance systems to meet the stringent regulatory requirements of global health authorities.
Lonza’s core offerings include active pharmaceutical ingredient (API) synthesis, formulation development, aseptic filling and packaging services, as well as cell-therapy and viral-vector manufacturing. Its specialty ingredients division delivers antimicrobial preservatives, cosmetic actives and nutritional ingredients that serve customer formulations across personal care, home care and food markets. Complementing these capabilities, Lonza provides technical support, regulatory guidance and supply-chain services designed to accelerate time to market and ensure product consistency at commercial scale.
The company maintains a global network of research, development and manufacturing sites across Europe, North America and the Asia-Pacific region, employing a multidisciplinary workforce of scientists, engineers and regulatory specialists. As of January 2022, Albert Baehny serves as Chief Executive Officer, leading a management team focused on sustainable growth, operational excellence and customer-centric innovation for the life sciences and specialty ingredients industries.
AI Generated. May Contain Errors.